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Introduction: The current study aimed at comparing the effect of oral contraceptive 
pills (OCPs) with expectant management in treatment of functional ovarian cysts. The 
study was conduct to compare the effect of hormone therapy with expectant 
management in the treatment of functional ovarian cysts. Hormone therapy for 
functional cysts is widely used in clinical practices, but the efficacy of this treatment is 
not determined. 
Methods: The current randomized, clinical trial was performed on 50 females with 
functional ovarian cysts (40 to 95 mm in diameter) in reproductive age, within the age 
range of 18 to 48 years, referred to the Clinic of Gynecological Diseases in a private 
hospital as outpatient from May 2015 to September 2016. The cysts were identified by 
transvaginal ultrasonography. All the patients had stable vital sign, mild to moderate 
abdominal discomfort. The patients were randomly divided into two equal groups and 
followed for eight consecutive weeks. Group A (n= 25) was observed without 
hormone therapy, only with some analgesics if needed, and the Group B (n=25) 
received OCPs. After follow-up period, cysts improvement status was compared 
between the groups. 
Results: Although nonsignificant, the chance of recovery reduced in patients with each 
passing year [(odds ratio (OR) =0.985; 95% confidence interval (CI): 0.902-1.077]. 
In addition to the insignificant results, the odds of improvement in the severe and 
moderate pain groups were 0.777 and 2.023 times higher than that of the mild pain 
group. The feeling of heaviness increased the odds of improvement by 1.161. As well, 
the patients who had cysts for more than three months were 1.264 times more prone 
to recovery than the ones with younger cysts. Nausea and the absence of internal echo 
inside the cysts decreased the odds of improvement. However, the impact of none of 
the abovementioned factors was significant on the treatment of cysts. 
Conclusions: Based on the results of the current study, the expectant management is 
as effective as OCPs for the treatment of functional ovarian cysts; in other words, the 
rate of disappearance of functional ovarian cyst was not affected by OCP use. However, 
further studies with larger sample sizes are needed to increase the study power and 





© 2018. International Journal of 
Cardiovascular Practice. 
INTRODUCTION
Ovarian cyst is a blister-like sac, which is formed on the 
surface of ovary during or after ovulation [1]. Most of 
them are made in reproductive age and are harmless [2]; 
these cysts do not cause any symptom and are resolved 
without treatment [3], but sometimes they cause health 
problems that require special attention, and even may 
lead to infertility [4]. Normal function of ovary is the 
periodic release of eggs and the production of the steroid 
hormones of estradiol and progesterone [5]. Both 
activities are integrated in the continuous repetitive 
process of follicle maturation, ovulation, and corpus 
luteum formation and regression. Mature follicle is 
ruptured and releases egg during ovulation and corpus 
luteum is produced from empty follicle [6]; if pregnancy 
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does not occur corpus luteum is regressed, due to the 
absence of hCG (human chorionic gonadotropin). 
Sometimes this procedure does not happen normally, 
which results in the formation of ovarian cysts [7]. 
Therefore, functional ovarian cysts are different from 
ovarian growths induced by other pathological 
problems [8]; most of them regress spontaneously in 
two or three cycles [9], but if a cyst gets large, it can twist, 
be ruptured, or bleed and become very painful [10]. A 
functional type of ovarian cyst forms because of slight 
changes in the way of making or releasing an egg by the 
ovary [11]. There are two types of such cysts: 1. The 
follicular cyst, which occurs when the sac on ovary does 
not release an egg and the sac swells up with fluid, 2. The 
luteal cyst, which is formed when the sac releases an egg 
and then reseals and fills with fluid [12]. Most functional 
ovarian cysts are asymptomatic [13], the larger the cyst, 
the more likely the symptom. The symptoms are pain or 
aching in lower abdomen, menstrual irregularity, vaginal 
bleeding, dyspareunia, etc.; sometimes the cyst is 
ruptured and causes peritoneal irritation with 
presentations such as nausea and vomiting or sudden 
onset of pain, hemorrhagic cyst, intra-abdominal 
bleeding, and emergency conditions [14]. Some other 
manifestations such as nausea and vomiting may be felt 
before the occurrence of such events [15]. Regular 
pelvic examination is recommended for some patients 
with the history of such cysts; they also may need regular 
sonography [16]. Oral contraceptive pills (OCPs) are 
prescribed by some physician to shrink the cyst, if it is 
persistent and makes discomfort [17]. Although it 
seems that they are not effective enough compared with 
close observation, and even some researchers reported 
no benefits for OCPs, some others prescribed them 
before any surgical practices [18]; therefore, the current 
study aimed at evaluating this issue. For this purpose, 
some patients who referred to a private clinic were 
selected in order to compare the effect of OCPs with 
close observation in the clinical management of 
functional ovarian cysts. 
METHODS 
The current randomized, clinical trial was performed on 
215 patients referring to the Gynecology Clinic in 
Alghadir Hospital as well as private offices in Tehran, 
Iran, from May 2015 to September 2016. In the current 
study, 145 patients were excluded due to exaggeration of 
the symptoms, need for surgery, etc.; therefore, 70 
patients participated in the study. All patients were 
selected randomly based on the computer-generated 
list. Demographic characteristics of the subjects were 
collected by a questionnaire; the subjects were defined 
as outpatient because of stable vital signs and no need 
for hospitalization; all of them had functional ovarian 
cysts based on vaginal ultrasound findings performed by 
the same specialist. The size of ovarian cysts ranged 40 
to 95 mm in diameter; most of the patients had mild to 
severe lower abdominal pain, feeling pressure, 
dyspareunia, or the cysts may be found accidentally on 
voluntary sonography without any symptoms. Finally, 
20 patients lost to follow-up due to exacerbation of 
conditions or other reasons; hence, a total of 50 patients 
were studied for eight weeks. Inclusion criteria were  
being in reproductive age from 18 to 48 years, 
euthyroidism, euprolactinemia, normotensive, no 
history of cystectomy, lack of overweight (body mass 
index (BMI) < 30 kg/m2), and having only functional 
cysts. Exclusion criteria were history of infertility, 
polycystic ovary (PCO) syndrome, endometrioma, 
dermoid cysts, and OCPs consumption during the last 
year. The patients were randomly divided into two equal 
groups: 
Group A were considered as the expectant management 
group without any medication, and Group B received 
OCPs. Both groups were followed up for eight 
consecutive weeks. After history-taking and preliminary 
examinations, ultrasonography was performed for each 
patient to confirm the presence of 40-95-mm cysts. 
Based on the assignments, patients received or not 
received medication. The participants' demographic 
and medical data such as age, level of pain, feeling 
heaviness in pelvis, nausea, duration of cyst formation (± 
3 months), and echogenic cysts were recorded and both 
groups were compared accordingly. Patients attending 
the clinic on every Wednesday were allocated to either 
expectant management or OCPs consumption groups. 
Group A were only given some analgesics, if they had an 
endurable pain, while group B were given low-dose 
OCPs for eight consecutive weeks. During follow-up 
period, all patients had the emergency call number to 
report any problem and were examined and evaluated 
weekly. The groups were compared based on the 
obtained data on nausea, feeling of pressure in the pelvis, 
echogenic cysts, and mild (a little sense of pressure, no 
need analgesic), moderate (any discomfort often need 
to use analgesic), or sever (permanent discomfort that 
causes continually use of analgesics) pain scored base on 
VAS (visual analogue scale; a method to measure a 
characteristic or attitude that is believed to range across 
a continuum of values). 
Statistical Analysis 
The descriptive characteristics of the continuous and 
categorical variables are expressed as mean (standard 
deviation (SD) and frequency (percentage), 
respectively. The normality assumption of the 
continuous variables was assessed by the Kolmogorov-
Smirnov test. The comparison between the continuous 
variables was done by independent samples t test. The 
cross tables between the categorical variables was 
analyzed using chi-square test. Logistic regression is a 
common statistical tool for predicting a binary outcome. 
In the employed model, the relationship between the 
independent and dependent variables was a logit 
function (the natural logarithm of odds), and not a 
linear one. The model was formulated as 





) = α + β1X1 +
β2X2 + ⋯ + βkXk + ε 
In the employed formula, X1, X2 , … , Xk  are the 
independent variables, and α, β1, β2, … , βk are the 
regression parameters, which should be estimated 
through the data. Statistical analysis was performed with 
SPSS version 16.0 (Chicago, IL, USA). All statistical 
tests were two-sided, and a P-value < 0.05 was 
considered the level of significance. 
RESULTS 
Based on the data obtained from 50 cases, 28 (56%) 
were improved and the mean (SD) was 30.280 (7.216). 
The descriptive statistics of the variables in two 
categories of improvement are shown in Table 2. 
 
Table 1: Descriptive Statistics of Variables in Different Groups 
Variable Total, N (%) Group, N (%) P-value 
  A B  
Age 30.280 (7.216) 30.120(7.031) 30.440(7.539) 0.877 
Pain    0.875 
Mild 22(44) 12(54.5) 10(45.5)  
Moderate 17(34) 8(47.1) 9(52.9)  
Severe 11(22) 5(45.5) 6(54.5)  
Heaviness    0.377 
No 32(64) 14(43.8) 18(56.3)  
Yes 18(36) 11(61.1) 7(38.9)  
Nausea    0.440 
No 42(84) 22(52.4) 20(47.6)  
Yes 8(16) 3(37.5) 5(62.5)  
Duration of cyst formation    0.390 
< 3 mo 29(58) 13(44.8) 16(55.2)  
> 3 mo 21(42) 12(57.1) 9(42.9)  
Improvement    0.087 
No 22(44) 14(63.6) 8(36.4)  
Yes 28(56) 11(39.3) 17(60.7)  
Internal echo inside the cysts    0.306 
Yes 11(22) 4(36.4) 7(63.6)  
No 39(78) 21(53.8) 18(46.2)  
 
Table 2: Descriptive Statistics of Variables in Different Categories of Improvement 
Variable Improvement, N (%) P-value 
 No Yes  
Age 30.363(7.537) 30.214(7.093) 0.943 
Pain   0.319 
Mild 11(50) 11(50)  
Moderate 5(29.4) 12(70.6)  
Severe 6(54.5) 5(45.5)  
Heaviness   0.962 
No 14(43.8) 18(56.3)  
Yes 8(44.4) 10(55.6)  
Nausea   0.250 
No 17(40.5) 25(59.5)  
Yes 5(62.5) 3(37.5)  
Duration of cysts formation   0.890 
<3 mo 13(44.8) 16(55.2)  
>3 mo 9(42.9) 12(57.1)  
Internal echo inside cyst   0.912 
Yes 5(45.5) 6(54.5)  
No 17(43.6) 22(56.4)  
None of the unadjusted results were significant in Table 
2. In other words, the unadjusted effect of the variables 
on positive/negative improvement was not statistically 
significant. The results of logistic regression analysis are 
shown in Table 3.
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Table 3: The Results of Logistic Regression assessing Improvement based on Several Variables 
Parameter Estimate SE P-value OR OR: 95%CI 
     Lower Higher 
Age -0.015 0.045 0.744 0.985 0.902 1.077 
Pain       
Severe to mild -0.252 0.832 0.762 0.777 0.152 3.972 
Moderate to mild 0.705 0.748 0.346 2.023 0.496 8.776 
Heaviness (yes) 0.149 0.677 0.826 1.161 0.308 4.384 
Nausea (yes) -0.833 0.920 0.365 0.435 0.072 2.640 
Duration(>3 mo) 0.234 0.657 0.722 1.264 0.348 4.586 
Internal (yes) 0.047 0.774 0.952 1.048 0.230 4.786 
Group (B) 1.186 0.655 0.070 3.275 0.907 11.822 
SE: Standard Error; OR: Odds Ratio; CI: Confidence Interval 
Although insignificant, chance of recovery is reduced in 
patients with each passing year (Odds Ratio (OR) = 
0.996, 95% Confidence Interval (CI): 0.907-1.094). 
The chance of improvement is reduced by each 
millimeter growth of the cyst in length (OR = 0.969, 
95% CI: 0.913-1.029); similarly, the chance of 
improvement is reduced by each millimeter growth of 
the cyst in width (OR = 0.997; 95%CI: 0.903-1.101). In 
addition to the insignificant results, the odds of 
improvement in the severe and moderate pain groups 
were 0.859 and 1.717 times higher than that of the mild 
pain group. The feeling of heaviness increases the odds 
of improvement by OR of 1.019. As well, those who had 
cysts for more than three months were 1.211 times more 
prone to experience improvement. Nausea decreased 
the odds of improvement. However, none of the 
abovementioned effect sizes were significant. Based on 
the results, the adjusted effect of group 
(medicine/expectation) was statistically significant in 
such an extent that the odds of improvement in the 
medicine group was 1.581 times higher than that of the 
expectation group (95%CI: 1.014-23.299). However, 
none of the variables affected the status of improvement 
in the adjusted format. Moreover, the results of receiver 
operating characteristic (ROC) curve showed an 
acceptable amount of prediction accuracy in the logistic 
regression model (Fig 1). Table 4 shows the accuracy of 
tools evaluated the results of the logistic regression and 
indicated an acceptable accuracy of the predicted values. 
Table 4 shows the accuracy of the tools evaluated the 
results of the logistic regression, which indicate an 
acceptable accuracy for the predicted values. 
 
 
Table 4: Accuracy of the Tools Assessed the Results of Logistic Regression 
 Estimate 95%CI 
Sensitivity 0.68 0.45-0.86 
Specificity 0.67 0.47-0.84 
Positive predictive value 0.62 0.47-0.75 
Negative predictive value 0.73 0.58-0.84 
Accuracy 0.68 0.53-0.80 
Area under curve 0.70 0.55-0.85 
DISCUSSION
Since OCPs were associated with a reduced incidence of 
functional ovarian cysts [19], epidemiologic studies 
reported adverse relationships between OCPs 
consumption and surgical remove of functional ovarian 
cysts [20]. Short-term treatment with OCPs was thus 
administered for the initial management of ovarian cysts 
[21]. However, other meta-analyses showed no 
difference between OCP consumption and placebo 
treatment outcomes in ovarian cysts; these masses 
should be monitored expectantly for several menstrual 
cycles [22]. If a cystic mass does not resolve after this 
timeframe, it is unlikely to be a functional cyst, and 
further workup may be indicated [23]. In 
postmenopausal patients, a persistent simple cyst 
smaller than 10 cm in the presence of a normal CA125 
value may be monitored with serial ultrasonographic 
examinations [24]. But some authors prescribed 
hormone therapy base on the patient’s characteristics 
such as age, size of the cyst, pain, and duration of 
persistent. Alcazar JL. et al., evaluated the results of 
expectant management of ovarian cysts with benign 
ultrasound morphology in asymptomatic 
premenopausal females [25]. 
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Figure 1: The ROC Curve of the Logistic Regression Results (AUC = 0.70; 95%CI: 0.55-0.85) 
In the case of cysts smaller than 80 mm, patients 
underwent follow-up protocol with transvaginal 
ultrasound examination with six months intervals for 
two years, 38.5% resolved spontaneously, 25.5% 
persisted without change, and 20.8% were surgically 
removed. They concluded that expectant of cysts with 
benign morphology is a management option in selected 
asymptomatic premenopausal females. Also, according 
to Mackenna’s study, 76% of functional ovarian cysts 
were resolved without any medication in first cycle and 
the remained ones were treated in the next menstrual 
cycle; on the other hand, all the persistent cysts were 
disappeared after the second cycle without any 
medication [26]. Review of 244 cases of ovarian cysts by 
Abdulabbar HS in Saudi University showed no benefits 
for hormone therapy in first and second cycles for 
resolution of ovarian cysts. Pascual MA conducted a 
retrospective observational cohort of 408 females with 
ovarian cysts from 2003 to 2013. During follow-up, 
31.8% of females underwent surgery due to physical 
discomfort and torsion of their cysts. In the current 
study, authors compared hormone therapy with 
observation; 56% were improved in the first cycle, 
although higher proportion in the medicine group were 
improved (P = 0.087). Ovarian cysts in both groups 
resolved within two cycles of either expectant 
management (Group A) or oral contraception (Group 
B), irrespective of the cyst diameter, feeling of pressure 
in lower abdomen, and present of internal echogenic 
cysts. Although the number of patients was small to 
reach a firm conclusion, the results observed in the 
current study were in agreement with those reported 
previously [27]. Steinkampf et al., and Ben–Ami et al., 
also (Shannon M Grabosch, MD 2017) suggested that 
the expectant management has the same effectiveness as 
oral estrogen/progestin therapy for the treatment of 
functional ovarian cysts [28]. Therefore, it seems 
unnecessary to prescribe pills to patients with functional 
ovarian cysts [29]. The authors prescribed low-dose 
pills, to minimize the possible side effects of OCPs; also 
the patients showed no interest to use them. Some 
authors prescribed other hormonal pills and showed 
resolution of the cysts [30]. 
CONCLUSIONS 
The study demonstrated no significant differences 
between two groups in the resolution of functional 
ovarian cyst. Based on the authors’ recommendations, if 
the patient had stable conditions, it is better to inform 
the patient about the possibility of spontaneous 
resolution. A larger sample size is required for future 
evaluation to get more exact conclusions. According to 
many articles and text books in gynecology, the first 
option to treat asymptomatic ovarian cysts is the 
expectant management.
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Figure 2: The Flowchart of the Patients’ Allocation
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